<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838097</url>
  </required_header>
  <id_info>
    <org_study_id>20070211</org_study_id>
    <nct_id>NCT00838097</nct_id>
  </id_info>
  <brief_title>European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa</brief_title>
  <official_title>A Prospective Registry Study Observing the Safety and Patterns of Use of Darbepoetin Alfa in EU Paediatric Chronic Kidney Disease Patients Receiving or Not Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This European study observes paediatric patients with Chronic Kidney Disease using
      Darbepoetin Alfa to assess the drug's long term safety and profile the patterns of its use
      within this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Drug Reactions (SADR), Serious Adverse Events (SAEs) or Events of Medical Interest (EMIs)</measure>
    <time_frame>2 years</time_frame>
    <description>An ADR was defined as an undesirable medical occurrence or worsening of a pre-existing medical condition that the investigator considered associated with the use of darbepoetin alfa. An AE is any untoward medical occurrence or worsening of a pre-existing condition whether or not considered to have a causal relationship with darbepoetin alfa. An SADR or SAE is any ADR or AE that is either: • Fatal • Life threatening • Requires or prolongs in-patient hospitalization • A persistent or significant disability/incapacity, or • A congenital anomaly/birth defect. An EMI is defined as one of the following pre-specified AEs: Thromboembolic Events (eg, venous thrombosis, embolism, vascular occlusion) • Seizures • Severe hypertension (Investigator discretion accompanied by recorded blood pressure) • Cardiovascular events (eg, cardiac arrhythmia, myocardial ischaemia/infarction, heart failure) • Pure red cell aplasia (PRCA) • Hypersensitivity reactions (eg, rash, urticaria, anaphylaxis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Concentration by Three Monthly Intervals</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Adjusted Darbepoetin Alfa Monthly Dose by Monthly Intervals</measure>
    <time_frame>Baseline and Months 1 to 24</time_frame>
    <description>Baseline dose = the daily dose equivalent x 30, where the daily dose equivalent = the last available dose prior to or at Day 1 / reported intended frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone Level by Three Monthly Intervals</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-serious Adverse Drug Reactions (ADRs)</measure>
    <time_frame>2 years</time_frame>
    <description>An ADR was defined as an undesirable medical occurrence or worsening of a pre-existing medical condition that the investigator considered associated with the use of darbepoetin alfa. A non-serious ADR was one in which none of the following applied:
Fatal
Life threatening
Required or prolonged in-patient hospitalization
A persistent or significant disability/incapacity, or
A congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">321</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Darbepoetin alfa</arm_group_label>
    <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Specialist Centres
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anaemia attributed to Chronic Kidney Disease (CKD)

          -  Sixteen years of age or under

          -  Documented CKD as demonstrated by estimated glomerular filtration rate (eGFR) &lt;60
             mL/min/1.73m² (Schwartz equation) for ≥3 months if not on dialysis, or: Receiving
             dialysis

          -  Treatment with darbepoetin alfa

          -  Documented informed consent by a parent or authorised individual, if required, and
             assent by the patient if appropriate

        Exclusion Criteria:

          -  Active malignancy or current chemotherapy or radiation therapy

          -  Investigator unlikely to be able to obtain adequate follow-up information, or
             participant will not be available for follow-up assessment

          -  Currently enrolled in or has not yet completed at least 30 days since ending other
             investigational device or drug study; subject receiving other investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <results_first_submitted>March 4, 2014</results_first_submitted>
  <results_first_submitted_qc>June 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2014</results_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Paediatric</keyword>
  <keyword>Darbepoetin Alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant was enrolled on 26 February 2008; last participant was enrolled on 24 February 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Darbepoetin Alfa</title>
          <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Darbepoetin Alfa</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set: all participants who received at least 1 dose of darbepoetin alfa during the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Darbepoetin Alfa</title>
          <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="319"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to &lt; 6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to &lt; 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not recorded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Drug Reactions (SADR), Serious Adverse Events (SAEs) or Events of Medical Interest (EMIs)</title>
        <description>An ADR was defined as an undesirable medical occurrence or worsening of a pre-existing medical condition that the investigator considered associated with the use of darbepoetin alfa. An AE is any untoward medical occurrence or worsening of a pre-existing condition whether or not considered to have a causal relationship with darbepoetin alfa. An SADR or SAE is any ADR or AE that is either: • Fatal • Life threatening • Requires or prolongs in-patient hospitalization • A persistent or significant disability/incapacity, or • A congenital anomaly/birth defect. An EMI is defined as one of the following pre-specified AEs: Thromboembolic Events (eg, venous thrombosis, embolism, vascular occlusion) • Seizures • Severe hypertension (Investigator discretion accompanied by recorded blood pressure) • Cardiovascular events (eg, cardiac arrhythmia, myocardial ischaemia/infarction, heart failure) • Pure red cell aplasia (PRCA) • Hypersensitivity reactions (eg, rash, urticaria, anaphylaxis).</description>
        <time_frame>2 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Drug Reactions (SADR), Serious Adverse Events (SAEs) or Events of Medical Interest (EMIs)</title>
          <description>An ADR was defined as an undesirable medical occurrence or worsening of a pre-existing medical condition that the investigator considered associated with the use of darbepoetin alfa. An AE is any untoward medical occurrence or worsening of a pre-existing condition whether or not considered to have a causal relationship with darbepoetin alfa. An SADR or SAE is any ADR or AE that is either: • Fatal • Life threatening • Requires or prolongs in-patient hospitalization • A persistent or significant disability/incapacity, or • A congenital anomaly/birth defect. An EMI is defined as one of the following pre-specified AEs: Thromboembolic Events (eg, venous thrombosis, embolism, vascular occlusion) • Seizures • Severe hypertension (Investigator discretion accompanied by recorded blood pressure) • Cardiovascular events (eg, cardiac arrhythmia, myocardial ischaemia/infarction, heart failure) • Pure red cell aplasia (PRCA) • Hypersensitivity reactions (eg, rash, urticaria, anaphylaxis).</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Drug Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Events of Medical Interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Concentration by Three Monthly Intervals</title>
        <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Concentration by Three Monthly Intervals</title>
          <population>Full analysis set</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.06" spread="1.62" lower_limit="10.88" upper_limit="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.47" spread="1.64" lower_limit="11.27" upper_limit="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="1.32" lower_limit="11.18" upper_limit="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.43" spread="1.50" lower_limit="11.24" upper_limit="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.39" spread="1.38" lower_limit="11.21" upper_limit="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.26" spread="1.35" lower_limit="11.08" upper_limit="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" spread="1.50" lower_limit="11.08" upper_limit="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" spread="1.34" lower_limit="11.09" upper_limit="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.42" spread="1.40" lower_limit="11.20" upper_limit="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Adjusted Darbepoetin Alfa Monthly Dose by Monthly Intervals</title>
        <description>Baseline dose = the daily dose equivalent x 30, where the daily dose equivalent = the last available dose prior to or at Day 1 / reported intended frequency.</description>
        <time_frame>Baseline and Months 1 to 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Adjusted Darbepoetin Alfa Monthly Dose by Monthly Intervals</title>
          <description>Baseline dose = the daily dose equivalent x 30, where the daily dose equivalent = the last available dose prior to or at Day 1 / reported intended frequency.</description>
          <population>Full analysis set</population>
          <units>μg/kg/month</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.82" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.74" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="1.75" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.76" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.69" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="1.65" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.69" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.60" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.61" upper_limit="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.52" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" lower_limit="1.47" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.53" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" lower_limit="1.49" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 13 (n=206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.40" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 (n=200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.46" upper_limit="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.52" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 16 (n=186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.51" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 17 (n=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.54" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.51" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 19 (n=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.50" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 20 (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" lower_limit="1.48" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.56" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 22 (n=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" lower_limit="1.46" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 23 (n=154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" lower_limit="1.41" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" lower_limit="1.22" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parathyroid Hormone Level by Three Monthly Intervals</title>
        <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone Level by Three Monthly Intervals</title>
          <population>Full analysis set</population>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.44" spread="1.62" lower_limit="11.82" upper_limit="36.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.76" spread="1.64" lower_limit="9.93" upper_limit="36.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.12" spread="1.32" lower_limit="9.87" upper_limit="29.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.70" spread="1.50" lower_limit="9.20" upper_limit="33.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.11" spread="1.38" lower_limit="8.55" upper_limit="33.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.51" spread="1.35" lower_limit="9.57" upper_limit="30.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.69" spread="1.50" lower_limit="9.56" upper_limit="36.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.12" spread="1.34" lower_limit="8.93" upper_limit="36.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.20" spread="1.40" lower_limit="11.13" upper_limit="35.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-serious Adverse Drug Reactions (ADRs)</title>
        <description>An ADR was defined as an undesirable medical occurrence or worsening of a pre-existing medical condition that the investigator considered associated with the use of darbepoetin alfa. A non-serious ADR was one in which none of the following applied:
Fatal
Life threatening
Required or prolonged in-patient hospitalization
A persistent or significant disability/incapacity, or
A congenital anomaly/birth defect.</description>
        <time_frame>2 years</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Darbepoetin Alfa</title>
            <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-serious Adverse Drug Reactions (ADRs)</title>
          <description>An ADR was defined as an undesirable medical occurrence or worsening of a pre-existing medical condition that the investigator considered associated with the use of darbepoetin alfa. A non-serious ADR was one in which none of the following applied:
Fatal
Life threatening
Required or prolonged in-patient hospitalization
A persistent or significant disability/incapacity, or
A congenital anomaly/birth defect.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>In this study only adverse drug reactions, serious adverse events and events of medical interest were collected. Other Adverse Events summarizes the non-serious occurrences of adverse drug reactions and non-serious occurrences of events of medical interest that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Darbepoetin Alfa</title>
          <description>Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital mitochondrial cytopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardiac output increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>HLA marker study positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Bladder dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Inadequate diet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

